Diametric Capital, LP Vertex Pharmaceuticals Inc Transaction History

Diametric Capital, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $515,334 - $576,780	1,639 New	1,639 $576,000
Q3 2020 Nov 13, 2020	SELL	$255.65 - $303.1 $955,108 - $1.13 Million	-3,736 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$225.48 - $295.8 $16,234 - $21,297	72 Added 1.97%	3,736 $1.09 Million
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $557,158 - $691,142	-2,789 Reduced 43.22%	3,664 $872,000
Q4 2019 Feb 14, 2020	SELL	$166.71 - $223.91 $677,509 - $909,970	-4,064 Reduced 38.64%	6,453 $1.41 Million
Q3 2019 Nov 13, 2019	BUY	$166.23 - $187.09 $1.75 Million - $1.97 Million	10,517 New	10,517 $1.78 Million
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $1.11 Million - $1.28 Million	-6,722 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $1.1 Million - $1.31 Million	6,722 New	6,722 $1.24 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.